HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Protega Pharmaceuticals Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Protega Pharmaceuticals Intelligence Report

Generated from 2 signals · 2 evidence sources

Type

Company Intelligence Report

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 76%

Evidence

12 items

Sources

5

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Protega Pharmaceuticals maintains an active intelligence profile across Pain Management, Opioid. 2 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with moderate portfolio impact. Evidence coverage stands at 76% across 2 tracked sources. Highest-priority development: FDA TA — ANDA219413. Regulatory precedent. Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as Protega Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA TA — ANDA219413

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA AP — ROXYBOND (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA AP — ROXYBOND (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    Imu-Tek Animal Health, Incorporated - 724610 - 06/05/2026

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Guidance Snapshot Pilot

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    Investigational New Drug (IND) Application

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    IND Application Reporting: IND Safety Reports

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA AP — ROXYBOND (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 36 with buyer quality 6 (Emerging). Competitive pressure: Low. Portfolio impact: Moderate.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA TA — ANDA219413

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ROXYBOND (SUPPL)

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ROXYBOND (SUPPL)

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Imu-Tek Animal Health, Incorporated - 724610 - 06/05/2026

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Guidance Snapshot Pilot

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Investigational New Drug (IND) Application

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • IND Application Reporting: IND Safety Reports

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ROXYBOND (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Accepts Supplement for RoxyBond by Protega Pharmaceuticals

    Pain Management · Opioid

  • FDA Accepts Supplement Application for RoxyBond (NDA209777)

    Pain Management · Opioid

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.